← Back to guidelines
Cardiology230 papers

Acute ST segment elevation myocardial infarction

Last edited: 4/14/2026

Overview

Acute ST segment elevation myocardial infarction (STEMI) is a life-threatening condition characterized by significant blockage of coronary arteries leading to myocardial necrosis, requiring urgent reperfusion therapy to minimize myocardial damage and improve outcomes.

Diagnosis

  • Electrocardiogram (ECG): Presence of ST-segment elevation ≥1 mm in two or more contiguous leads 1.
  • Cardiac biomarkers: Elevated troponin levels confirm myocardial necrosis 1.
  • Coronary angiography: Definitive diagnosis and assessment of coronary artery occlusion 1.
  • Management

  • Primary Percutaneous Coronary Intervention (PCI): Recommended as the preferred reperfusion strategy 1.
  • Anticoagulation: Bivalirudin-based anticoagulation over heparin reduces net clinical events, major adverse cardiac events, bleeding, and mortality 1.
  • Antiplatelet Therapy: Early administration of abciximab pre-hospital and adjunctive thrombus aspiration may enhance ST-segment resolution and reduce distal embolization 3.
  • Collateral Circulation: Presence of angiographically visible collateral flow is associated with improved prognosis, particularly in patients with TIMI 0/1 flow 2.
  • Special Populations

  • Elderly: No specific recommendations provided in the abstracts.
  • Comorbidities: No specific adjustments to treatment based on comorbidities mentioned; however, careful consideration of bleeding risk with bivalirudin is advised 1.
  • Key Recommendations

  • Use bivalirudin-based anticoagulation during PCI for STEMI patients to reduce major adverse events and bleeding compared to heparin 1 (Evidence: Strong).
  • Activate cardiac catheterization team concurrently by emergency physicians to optimize door-to-balloon times 4 (Evidence: Moderate).
  • Consider thrombus aspiration as an adjunctive therapy in STEMI patients receiving early abciximab to improve reperfusion outcomes 3 (Evidence: Moderate).
  • References

    1 Oli PR, Shrestha DB, Shtembari J, Gyawali P, Regmi L, Bhandari A et al.. Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis. Coronary artery disease 2023. link 2 Alsanjari O, Chouari T, Williams T, Myat A, Sambu N, Blows L et al.. Angiographically visible coronary artery collateral circulation improves prognosis in patients presenting with acute ST segment-elevation myocardial infarction. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2020. link 3 Ahmed TA, Atary JZ, Wolterbeek R, Hasan-Ali H, Abdel-Kader SS, Schalij MJ et al.. Aspiration thrombectomy during primary percutaneous coronary intervention as adjunctive therapy to early (in-ambulance) abciximab administration in patients with acute ST elevation myocardial infarction: an analysis from Leiden MISSION! acute myocardial infarction treatment optimization program. Journal of interventional cardiology 2012. link 4 Kraft PL, Newman S, Hanson D, Anderson W, Bastani A. Emergency physician discretion to activate the cardiac catheterization team decreases door-to-balloon time for acute ST-elevation myocardial infarction. Annals of emergency medicine 2007. link

    Original source

    1. [1]
      Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis.Oli PR, Shrestha DB, Shtembari J, Gyawali P, Regmi L, Bhandari A et al. Coronary artery disease (2023)
    2. [2]
      Angiographically visible coronary artery collateral circulation improves prognosis in patients presenting with acute ST segment-elevation myocardial infarction.Alsanjari O, Chouari T, Williams T, Myat A, Sambu N, Blows L et al. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2020)
    3. [3]
    4. [4]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG